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Reforming the ethical review system: balancing the rights and interests of research participants 
with the duty to facilitate good research 
E Cave and C Nichols* 
Abstract 
Researchers have frequently complained that the NHS ethical review system stifles good research. 
At last measures are being put in place to address this criticism, but will they undermine the 
protection of research participants? The Declaration of Helsinki recognizes that medicine will not 
progress without good quality research, but also demands that the well-being of research 
participants takes precedence over the interests of science and society. This article examines the 
implications of the ongoing reform of the NHS research ethics review system for researchers, ethics 
committees and research participants. 
 
Introduction 
The Declaration of Helsinki states in paragraph 5: ‘In medical 
research on human subjects, considerations related to 
the wellbeing of the human subject should take precedence 
over the interests of science and society’.1 But this 
principle should not be read in isolation. Paragraph 4 
acknowledges that ‘medical progress is based on research 
which ultimately must rest in part on experimentation 
involving human subjects’. In order for science to progress, 
good research must be facilitated. A narrow interpretation 
of paragraph 5 would lead to serious restrictions on 
research, of which uncertainty of outcome is an inherent 
feature. If protecting the wellbeing of the participant 
required risk to be eliminated, most research projects 
would be untenable. John Harris, for example, calls for a 
wider interpretation based on the benefit patients and 
research participants gain from living in a society where 
good research is prioritized.2 If this is accepted, and we suggest 
that it should be, then what the Declaration demands 
is that the risk to participants is carefully controlled. It 
must not be undue or excessive. Participants’ rights must 
be respected and exploitation must be avoided. It can ask 
no more, for to do so would seriously limit medical 
progress, contrary to the public good. The balancing of the 
imperatives contained in paragraphs 4 and 5 is the key to 
ethical research, as is reflected in the Central Office for 
Research Ethics Committees’ (COREC) Governance 
Arrangements for Research Ethics Committees (GAfREC).3 
Research ethics committees (RECs) are responsible for 
acting primarily in the interests of potential research participants 
and concerned communities, but they should also 
take into account the interests, needs and safety of 
researchers who are trying to undertake research of good 
quality. However, the goals of research and researcher, 
while important, should always be secondary to the dignity, 
rights and wellbeing of the research participant.3 
 
Recently, a number of reforms have been introduced 
which aim to facilitate research by bringing together 
aspects of research governance, and standardize protection 
of participants. They address Research and 
Development (R&D) and ethical review, both of which 
are required before an NHS research project can be initiated. 
The Clinical Trials Directive aims to foster harmonization 
and greater efficiency in the process of ethical 
review of clinical trials throughout Europe.4 In the UK, 
the effects of corresponding domestic legislation and the 
lobbying of disgruntled researchers have necessitated 
reform of the NHS ethical review system, which forms 
the focus of this paper. A new ethical review service will 
be created, but whom will it serve? Is an appropriate balance 
between facilitation of research and protection of 
research participants achieved? 
 
Responding to researchers’ needs 
Prior to 1991, RECs in the UK operated on an informal 
basis. The model was very much one of professional self regulation. 
The Declaration of Helsinki and the experience 
of the volunteers who served on ethics committees 
formed the basis for ethical decision making. However, 
changing attitudes to medical paternalism meant that 
greater openness and accountability were required. NHS 
RECs were formally recognized in Department of Health 
guidelines for the first time in 1991,5 marking the start of 
the current trend towards greater governmental oversight 
and control. In 1997 multicentre research ethics committees 
were introduced to review research taking place at more than  
one research site,6 but the process remained 
cumbersome. The Central Office for NHS Research Ethics 
Committees was set up in 2000 to improve the system, but 
researchers complained of additional bureaucracy.7 The 
work of RECs became increasingly complex, both as a 
result of advances in medical science and an increase in 
the quantity and complexity of legislation which has 
tended to encroach into ethical matters previously left to 
the discretion of RECs.8 Resentment amongst the research 
community grew. The time and effort involved in gaining 
ethical approval was felt to be disproportionate to the ethical 
significance of the research, especially where the risks 
to the participant were minimal.9 Uncertainty and disagreement 
over the remit of RECs both in terms of the 
types of activities that require ethical approval and the 
extent to which interference with the scientific design is 
ethically justified have also been problematical. The 
Medicines for Human Use (Clinical Trials) Regulations 
2004 (Clinical Trials Regulations) was introduced to 
implement the European Clinical Trials Directive. The 
remit of ethics committees was diminished. The scientific 
merit of the protocol is no longer the responsibility of 
RECs. The UK Ethics Committee Authority (UKECA) 
was established to oversee the ethical approval of clinical 
trials and the National Patient Safety Agency (NPSA) 
took over responsibility for COREC in 2005 to institute 
further reform following a report from an Ad Hoc 
Advisory Group in 2005.10 In the following sections we 
assess the extent to which the Clinical Trials Regulations 
and the current reforms of the NHS-REC system11 manage 
to resolve these issues without jeopardizing the rights and 
interests of research participants. 
 
Clinical trials 
 
In terms of recognizing the need to strike a fair balance 
between the rights and interests of research participants 
and the duty to support good quality medical research the 
objectives of the EU Clinical Trials Directive are sound. 
The preamble to the Directive emphasizes the importance 
of obtaining the consent of research participants whenever 
possible. The need to protect the wider interests of 
research participants is also emphasized, particularly in the 
case of research involving vulnerable groups incapable of 
expressing their consent.12 At the same time the Directive 
recognizes that the application of different procedural and 
ethical requirements in different Member States has led to 
unacceptable delays and complications in obtaining 
approval for important research.13 
 
The EU Directive has been implemented in the UK 
by the Clinical Trials Regulations which, in addition to 
ensuring the advantages of uniformity throughout Europe, 
aim to facilitate the process of obtaining ethical approval 
for clinical trials conducted entirely within the UK. 
Specific measures to facilitate ethical approval of clinical 
trials include the requirement for a single favourable opinion 
regardless of how many sites are involved in the trial.14 
Ethics committees must give their opinion within a specified 
time limit, which would normally be 60 days,15 and 
they are also limited to a single request for further information. 
16 So long as the substance and quality of ethical 
review are maintained these procedural measures will not 
necessarily weaken the protection of research participants. 
There are, however, two potential areas of concern where 
it is possible that the Clinical Trials Regulations lower the 
standard of protection afforded to research participants. 
 
The first area of concern is that the ethical standards 
incorporated by the Clinical Trials Regulations are based 
on an outdated version of the Declaration of Helsinki in 
which the protection afforded to research participants is 
less extensive than under the current version. The 
Clinical Trials Directive and the subsequent Good 
Clinical Practice Directive17 refer only to the 1996 version 
of the Declaration, which was substantially re-written in 
2000 and amended again in 2002 and 2004. In the UK, 
the Clinical Trials Regulations refer to the 1964 
Declaration of Helsinki as amended in 1975, 1983, 1989 
and 1996, but the subsequent amendments are ignored.18 
 
The aim of the revision in 2000 was to enhance the 
protection of research participants. The most significant 
changes concern paragraphs 29 and 30, which relate to 
placebo-controlled trials and post-trial access to treatment. 
Paragraph 29 demands that new methods are tested 
‘against those of the best current prophylactic, diagnostic, 
and therapeutic methods’. Arguably this would compromise 
the scientific basis of research and even prevent 
research in developing countries where the cost of the 
best-proven treatment may be prohibitive. Paragraph 30 
requires that: ‘At the conclusion of the study every patient 
entered into the study should be assured of access to the 
best proven ... methods identified by the study’. But who 
should foot the bill? Such was the controversy19 that notes 
of clarification were added in 2002 and 2004, respectively. 
Cases where placebo-controlled trials may be viewed as 
ethically acceptable despite the existence of proven therapy 
are listed, and the requirement of continued access is 
left to the adjudication of ethics committees. Paragraph 29 
and 30 were set down in the interests of protecting participants. 
Their subsequent amendments and the emphasis in 
the European Directive and UK Regulations on the 1996 
rather than the 2000 version, emphasize the importance of 
good science. There is deemed to be adequate protection 
of research participants in the outdated version of the 
Helsinki Declaration. 
 
Second, and of potentially greater concern, is that the 
role of ethics committees under the Clinical Trials 
Regulations is curtailed and subject to greater political 
influence. Previously, ethics committees exercised a great 
deal of discretion in forming a view as to whether a 
research proposal was consistent with broad ethical principles. 
Now they are directed ‘in particular’ to consider the 
‘relevant matters’ set out in Regulation 15. In summary, 
those relevant matters include a consideration of the relevance 
of the trial and the design; the balance of benefits 
and burdens; the protocol; the suitability of the investigator 
and the facilities; the information and procedure for 
obtaining informed consent; financial arrangements, 
including sources of funding, payments to the subject and 
investigator; and insurance or indemnity arrangements to 
cover legal liabilities in the event of death or injury. 
Rather than being based on an unfettered interpretation of 
the Declaration of Helsinki, the decision of an ethics committee 
should now be referable to one or more of these relevant 
matters. 
 
The Clinical Trials Directive requires statutory authorization 
of ethics committees reviewing clinical trials. In the UK,  
rather than create specialist ethics committees to 
deal only with clinical trials, the decision was made to 
authorize certain ethics committees within and outside the 
NHS to review clinical trials in addition to other research. 
Consequently UKECA – formed in May 2004 – now 
authorizes a number of ethics committees. Others exist 
outside its authority and they may continue to review 
research other than clinical trials. For many committees, 
however, the era of self-regulation has ended. Whilst 
UKECA is independent of the medical profession it is not 
independent of the Government. As a result, some fear 
that the Government’s emphasis on the potential economic 
benefits of research might lead to the removal of 
ethical barriers.20 
 
The moral duty to support research of good quality 
derives from the contribution it makes to the public 
good.22 As a result, ethics committees not only have a 
duty to investigators and research participants, but also a 
wider duty to society. It is appropriate that RECs should 
be publicly accountable for their conduct and decisions. 
The Clinical Trials Directive recognizes this and seeks to 
make ethics committees more accountable by laying down 
clear and transparent guidelines for their operation.21 In 
the UK these guidelines are incorporated into the 
Clinical Trials Regulations. Ethics committees are therein 
made responsible to UKECA to ensure that they perform 
their duties in accordance with the Regulations. UKECA 
has wide ranging powers. They include the power to 
authorize ethics committees to undertake review of clinical 
trials, monitor their performance and, importantly, to 
provide advice and assistance.22 Additionally, the chairman 
and two other members of each committee are 
appointed by UKECA.23 Whilst a significant degree of 
independence, in terms of operation, decision-making 
and membership is lost, the important question is whether 
or not the trade-off between independence and accountability 
is proportionate. 
 
Similar arrangements for political oversight of ethics 
committees are in place elsewhere in Europe. In Denmark 
for example, the Minister for Science, Technology and 
Development appoints the chairman and one other member 
of the Danish National Committee for Biomedical 
Research. A further two members are appointed by the 
Minister for the Interior and Health.24 The Declaration of 
Helsinki states only that ethics committees should be 
independent of the investigator and the sponsor, not that 
they should be independent of the government. Moreover, 
the Declaration states that ethics committees should be 
constituted in accordance with the laws and regulations of 
the state, which itself implies a degree of political control. 
One of the aims of the Clinical Trials Directive is to 
ensure the continued public confidence in clinical trials 
and the ethics review system. Increased political accountability 
and the end of self-regulation may in fact contribute 
to this objective by increasing the independence or 
perceived independence of ethics committees from the 
medical and research professions. 
Concerns have been raised that the newly fettered 
RECs have been ‘hamstrung by Europe’25 and ‘may no 
longer be able to function because of political control’.26 
On the other hand, political oversight of ethics committees 
does not necessarily mean that the interests of 
research participants will be jeopardized. The Clinical Trials  
Regulations may usher in a new era of greater 
accountability and reassure the public of the quality of 
ethical review and of the independence of ethics committees 
from the medical and research professions. The important 
question is whether the more restricted role of ethics 
committees is justified, bearing in mind the need to balance 
the interests of science and society in facilitating 
research with the rights and interests of research participants. 
Ethics committees exist to protect research participants 
from harmful and unethical research, but the 
Declaration of Helsinki also tells us that the interests of 
participants must be balanced by society’s interest in continued 
medical progress. John Harris goes further.22 He 
argues that there is a moral duty to conduct medical 
research of good quality, and calls for a wide interpretation 
of paragraph 5 of the Declaration of Helsinki and for a 
new principle to be inserted: 
 
‘Biomedical research involving human subjects cannot legitimately 
be neglected, and is therefore both permissible and 
mandatory, where the importance of the objective is great 
and the risks to and the possibility of exploitation of fully 
informed and consenting subjects is small.’ 
 
This suggests that the intensity of ethical review 
should be no greater than what is minimally required to 
safeguard against the exposure of consenting research participants 
to undue risk and exploitation. That is not to say 
that the moral duties of investigators towards participants 
should be weakened. The principles expressed in the 
Declaration of Helsinki are primarily addressed to ‘physicians 
and other participants in medical research involving 
human subjects’.27 The more restricted remit of ethics 
committees under the Clinical Trials Regulations ensures 
that moral and legal responsibility for the safe conduct of 
research in accordance with principles of good clinical 
practice lies primarily with the investigator. Whilst this 
might entail that greater emphasis should be placed on 
ethics training for investigators, it is surely preferable to an 
overly intrusive ethics review system. 
 
Protecting the participant 
Fears that the measures introduced to facilitate research 
will lead to poorer protection of participants must be balanced 
with new measures contained in the Directive and 
the UK Regulations to ensure their protection. The 
Regulations reinforce the obligations of the investigator 
with the introduction of criminal sanctions for, amongst 
other things, commencing a clinical trial without ethical 
approval or making false or misleading statements that 
their research complies with principles of good clinical 
practice.28 Other measures to ensure the protection of 
research participants include greater powers of inspection 
and monitoring of clinical trials – particularly adverse 
event reporting.29 Informed consent and the protection of 
confidentiality ensure that the rights and interests of participants 
are more uniformly protected, and vulnerable 
participants who cannot consent are rigorously protected 
in the new legislation, arguably to the detriment of 
research in those areas.30 
 
We suggest that whilst there is greater danger that the 
interests of research participants will not always be protected 
to the extent that they were previously, the Regulations  
contain sufficient safeguards to ensure that 
research participants are not exposed to undue risk. The 
scope of ethical review is appropriately limited bearing in 
mind the duty not to impede research of good quality. The 
supposed threat to the independence of ethics committees 
from political oversight can be overstated. As ethics committees 
are now charged with performing statutory duties 
and must act in the public interest, we also suggest that it 
is appropriate that ethics committees should be accountable 
to a political authority. The Clinical Trials 
Regulations are thus a proportionate response to the need 
for both independence and accountability in the ethical 
review system. 
 
Other types of human research 
Only 15% of research applications concern clinical trials.31 
Outside the realm of clinical trials, ethical review of NHS 
research is subject to the guidelines contained in the 
Research Governance Framework and GAfREC.33 Whilst 
some of the new facilitative measures contained in the 
Clinical Trials Directive will apply to all NHS research, 
the protective measures contained in the Clinical Trials 
Regulations apply only to clinical trials. Facilitative measures 
include the imposition of a 60-day time limit on the 
review procedure and require a single UK-wide opinion for 
multicentre research. This alteration will benefit single centre 
and multicentre research, as well as clinical and 
non-clinical research. GAfREC is largely concerned with 
process, but also lists the requirements for a favourable 
ethics committee opinion. Informed consent is amongst 
them,32 but some of the other safeguards built into the 
Clinical Trials Regulations, such as guidelines relating to 
participants who cannot give informed consent, are absent 
or only vaguely expressed in GAfREC. Care must be taken 
to ensure that the new measures to facilitate NHS research 
do not weaken the protection of research participants. 
 
Some countries (Belgium, Denmark, The Netherlands 
and France) have extended the scope of the Clinical Trials 
Directive to all ‘biomedical research involving humans’.30 
If, as we suggest, the Directive strikes the right balance 
between facilitating research and protecting research participants, 
should we not extend the scope of the UK 
Regulations to all biomedical research on human subjects? 
 
One potential barrier to this approach is that unlike clinical 
trials, which form a reasonably homogeneous subset of 
research activities, ‘biomedical research on human subjects’ 
encompasses various activities that differ greatly in 
their methodology and risk profile. Even within the realm 
of clinical trials there are significant differences between 
phase I trials and phase IV trials, for instance. Some have 
argued that the requirements of the Regulations are excessive 
in relation to non-commercial research where the 
objective is to investigate the effectiveness of licensed 
medicines.33 As a result, the stringent and formal requirements 
of the Clinical Trials Regulations may be excessive 
where the burdens and risks imposed on research participants 
are small. 
 
A second problem that would have to be overcome if 
the Clinical Trials Directive were applied to all human 
research is the difficulty of distinguishing research from 
other activities. Whilst research is easily defined as an 
activity aimed at the acquisition of generalizable new  
knowledge, it is much more difficult – impossible even – to 
differentiate exclusively between (i) research and treatment, 
and (ii) research and clinical audit/service evaluation. 
 
As Lewens argues, this is because a single activity 
may be multifunctional.34 There is, therefore, a grey area 
that encompasses activities that are both research and 
treatment (or audit). Whilst such activities may be said to 
be more or less like research, or more or less like treatment 
(or audit), the boundaries are blurred and it becomes a 
matter of judgement as to which set of regulations should 
be applied. We suggest that within this uncertain area it is 
inappropriate to lay down rigid legal criteria, particularly 
where – as in the case of the Clinical Trials Regulations – 
they may be enforced by criminal sanctions. 
 
With the exception of research involving NHS staff, 
the remit of the new ethical review service will not differ 
significantly from the current remit set out in GAfREC.35 
As Ashcroft et al. rightly observe, the forthcoming reforms 
of the NHS research ethics service do not solve the problem 
of differentiating research from other activities.36 The 
Ad Hoc Advisory Group recommended that the remit of 
NHS RECs should not in future include surveys and other 
non-research activities if they present no material ethical 
issues,37 which implies that non-research activities should 
be reviewed if there are significant risks. A similar 
approach has been adopted in Australia. There the troublesome 
distinction between research and audit is avoided 
by emphasizing risk rather than purpose as the primary criterion 
for ethical review.38 However, COREC and the 
NPSA rejected this approach, preferring to maintain the 
status quo whereby audit is excluded from the remit of the 
research ethics service.39 Alternatively, a triage system is 
to be introduced, which aims to make the intensity of ethical 
review more sensitive to the ethical significance of the 
proposed activity. Under the proposed system, applications 
will be screened and those with no material ethical issues 
fast-tracked. Ethics advisers will be at hand to provide 
guidance. Triage only addresses half of the problem with 
the remit of ethics committees; approval of research that 
does not present any significant ethical issues is dealt with 
more proportionately, but audits that do present material 
ethical issues will still evade the review process, potentially 
putting participants at risk. In this respect triage is 
no worse than the current system and there are efficiency 
benefits for researchers, but an opportunity to protect participants 
from unethical audit and avoid the troublesome 
definition of research has been missed. 
 
The extent to which the interests of research participants 
are protected will depend on the quality of review 
undertaken at screening and by the new ethics advisers 
and their interpretation of the threshold criteria of ‘minimal 
risk’ and ‘no material ethical issues’. A discussion of 
these criteria is outside the scope of this article, but they 
are not black and white categories and involve a significant 
degree of ethical judgement. Diversely constituted 
committees are well suited to the deliberative nature of 
ethical decision making and something important is lost 
by relying on individual ethics advisers. Moreover, it is 
not clear how independent the decisions of ethics advisers 
will be given, that they will be employed by a research 
ethics service, which – as the tenor of the reforms demonstrate 
– is sensitive to the interests of the research community. 
There are dangers that the degree of protection 
afforded to the interests of research participants will not be 
as high as was previously the case, but this must be balanced 
by the justified concerns of researchers that much 
good research was impeded by excessive delays and disproportionate 
review. Elsewhere in Europe it is common to 
limit the remit of ethics committees by excluding certain 
types of research.40 In Denmark and The Netherlands for 
example, surveys and questionnaires do not require ethical 
review. The scope of ethical review is even more restricted 
elsewhere: in France ethical approval is only required for 
studies involving medical intervention, medication or 
physical risk; and in Austria REC approval is only required 
for clinical trials involving drugs. Whilst the rationale for 
this approach is that the excluded activities do not usually 
present any significant ethical issues, the danger is that 
they may do sometimes. Where this is the case and such 
studies are not subject to independent ethical scrutiny, 
participants will be put at greater risk. In the UK such 
studies would be picked up at screening and are more 
likely to be reviewed by an ethics committee. The triage 
system therefore retains the breadth of oversight of 
research that was a particular strength of the previous 
ethics committee system, but achieves this in a manner 
that is more sensitive and proportionate to the ethical significance 
of the proposed activity. 
 
Conclusion 
The Declaration of Helsinki recognizes that a balance needs 
to be struck between the interests of research participants 
and the interests of society in continued medical progress. 
John Harris goes further, arguing that there is a moral duty 
to facilitate, conduct and even participate in medical 
research of good quality.2 In the past the research community 
has complained that the ethical review system weighs 
the balance too much in favour of research participants. 
 
Following the introduction of the Clinical Trials 
Directive and the ongoing reform of the UK NHS-REC system, 
a rigorous and bureaucratic process that gave substantial 
freedom to ethics committees has given way to a more 
streamlined process with curtailed freedom to ethics committees. 
There is now a danger that the balance has swung 
too far in the other direction and that the interests of 
research participants are no longer adequately protected. 
 
We have argued that in relation to clinical trials the protection 
of research participants’ interests has been diminished 
in two ways. First, the Clinical Trials Directive and the UK 
Regulations endorse an outdated version of the Declaration 
of Helsinki, which affords research participants a lower standard 
of protection than the current version. Second, oversight 
by UKECA and the end of self-regulation means that 
ethics committees are no longer free from political influence. 
Nevertheless, it is our view that research ethics committees 
retain enough freedom to counter these factors. 
 
Measures designed to bring about a level of consistency do 
not always work against the interests of the participant. 
Indeed, better training and networking of ethics committee 
members, better communication and the sharing of case 
studies can and will lead to greater protection of participants. 
In addition, the Clinical Trials Regulations contain 
significant new measures that will serve to protect the consenting 
participant from exploitation and undue risk. 
Research falling outside the remit of the Clinical 
Trials Regulations poses more of a problem. Though facilitative 
measures will apply in practice to all NHS 
research, the protective measures contained in the 
Regulations will not. The approval of research by individual 
ethics advisers and the narrower remit of ethics committees 
will reduce the quality of ethical review and 
potentially expose participants in non-clinical trials to 
greater risk. However, reform has been necessary to ensure 
that research of good quality is not unjustifiably impeded. 
Whilst the role of ethics committees has been weakened 
and more emphasis placed on the responsibility of the 
investigator, this does not necessarily mean that research 
participants are vulnerable. Ethics committees provide 
just one of a number of safeguards and the Department of 
Health and professional bodies will need to review their 
guidance to researchers and ethics committees to take this 
into account. 
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